Boom in weight-loss drugs could lead to fall in beer sales, Heineken warns UK pubs
Reported by The Guardian Business, not nibnow. We are not the publisher of this story, only the source is.
Heineken warns that the growing use of GLP‑1 weight‑loss drugs could cut demand for beer and cider, potentially hurting the revenues of UK pubs and the broader hospitality sector.
World’s second largest brewer says use of drugs such as Wegovy can reduce desire to drink alcohol Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider. The world’s second-largest brewer sent a presentation to British hospitality customers earlier this month that said the use of GLP-1 medication – such as Ozempic and Wegovy – could reduce the desire to drink alcohol. This in turn could result in “fullness and fe
GLP‑1 medications such as Ozempic and Wegovy are drugs that suppress appetite and are increasingly popular for weight loss; Heineken is the world’s second‑largest brewer and a major supplier to British pubs, so changes in drinking habits directly affect its market.
- •Monitoring of beer and cider sales figures in the UK over the coming months
- •Statements or actions from pub trade groups responding to the potential decline
- •Any further research or industry surveys on how GLP‑1 drug use influences alcohol consumption